SciTech Development
SciTech Development, a US-based specialty pharma company, pioneers in engineering and patenting innovative cancer treatments.
SciTech Development, a US-based specialty pharma company, pioneers in engineering and patenting innovative cancer treatments.
SciTech Development, founded in Grosse Pointe Farms, United States, is a specialty pharmaceutical company dedicated to advancing cancer treatment. The company's core mission is to develop safer and more effective cancer therapies through innovative drug delivery systems. Its flagship product, ST-001-nanoFenretinide, combines their proprietary Drug Delivery Platform (SDP) with the promising anticancer drug fenretinide. SciTech's focus is on creating broadly applicable cancer treatments that can be patented and brought to market to improve patient outcomes.
Notable figures affiliated with SciTech Development include a team of experienced scientists and industry professionals committed to pioneering cancer therapies. The company has successfully raised $3.2 million to expand clinical trials for its lead drug candidate, demonstrating significant investor confidence. SciTech's achievements in drug development and delivery have positioned it as a promising player in the oncology pharmaceutical sector, with the potential to make a substantial impact on cancer treatment worldwide.
Companies similar to SciTech Development include NantBio, ZY Therapeutics, Otricath and PanTher Therapeutics.
SciTech Development was founded in 2001.
SciTech Development's headquarters is located in Grosse Pointe Farms, MI, US.
SciTech Development's most recent funding round was for $2.7M (USD) in June 2023.
As of Jun 7, 2023, SciTech Development has disclosed funding of $2.7M (USD). Undisclosed round amounts are excluded.
SciTech Development has 10 employees as of Feb 5, 2024.
PanTher Therapeutics
panthertx.com
